Abstract
The canine metabolic diseases, such as obesity and diabetes, have become a worldwide problem. Fibroblast growth factor 21 (FGF21) is a potent regulator which has many biological functions relative to metabolism regulation. It suggests that FGF21 plays important roles in regulating canine metabolic diseases. To acquire the recombinant canine FGF21 (rcFGF21) in Escherichia coli, the recombinant bacteria were induced by 0.5 mM IPTG for 16 hours at 16 °C, and the rcFGF21 protein was purified by Ni-NTA. 8 mg rcFGF21 was acquired from one liter bacteria. The rcFGF21 protein has specific immunoblot reactivity against anti-FGF21 and anti-His antibody. The in vivo experimental result showed that rcFGF21 can significantly reduce plasma glucose of STZ-induced diabetic mice.
Keywords: Recombinant canine FGF21, Escherichia coli, purification, plasma glucose.
Protein & Peptide Letters
Title:Expression, Purification and Characterization of Recombinant Canine FGF21 in Escherichia coli
Volume: 23 Issue: 9
Author(s): Zhong Zhenga, Chengjun Yanga, Ruofeng Yinb, Jinxi Jiangc, Haiting Hea, Xinxin Wanga, Mujie Kan and Yechen Xiao
Affiliation:
Keywords: Recombinant canine FGF21, Escherichia coli, purification, plasma glucose.
Abstract: The canine metabolic diseases, such as obesity and diabetes, have become a worldwide problem. Fibroblast growth factor 21 (FGF21) is a potent regulator which has many biological functions relative to metabolism regulation. It suggests that FGF21 plays important roles in regulating canine metabolic diseases. To acquire the recombinant canine FGF21 (rcFGF21) in Escherichia coli, the recombinant bacteria were induced by 0.5 mM IPTG for 16 hours at 16 °C, and the rcFGF21 protein was purified by Ni-NTA. 8 mg rcFGF21 was acquired from one liter bacteria. The rcFGF21 protein has specific immunoblot reactivity against anti-FGF21 and anti-His antibody. The in vivo experimental result showed that rcFGF21 can significantly reduce plasma glucose of STZ-induced diabetic mice.
Export Options
About this article
Cite this article as:
Zhenga Zhong, Yanga Chengjun, Yinb Ruofeng, Jiangc Jinxi, Hea Haiting, Wanga Xinxin, Kan Mujie and Xiao Yechen, Expression, Purification and Characterization of Recombinant Canine FGF21 in Escherichia coli, Protein & Peptide Letters 2016; 23 (9) . https://dx.doi.org/10.2174/0929866523666160628091657
DOI https://dx.doi.org/10.2174/0929866523666160628091657 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Hormone Responsive Breast Cancer and BRCA1 Mutation: Mechanism, Regulation and Iron-mediated Effects
Current Pharmaceutical Biotechnology Recent Patents on Rho Signaling Pathway as Therapeutic Target for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Invertebrate FMRFamide Related Peptides
Protein & Peptide Letters Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology A Validated UPLC Method Used for the Determination of Trandolapril and its Degradation Products as per ICH Guidelines
Current Pharmaceutical Analysis Effects of Therapeutic Hypothermia on the Glial Proteome and Phenotype
Current Protein & Peptide Science Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity
Mini-Reviews in Medicinal Chemistry Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention
Current Vascular Pharmacology Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Antisense Antibiotics: A Brief Review of Novel Target Discovery and Delivery
Current Drug Discovery Technologies Angiotensin I-Converting Enzyme: A Pathogenetic Role in Diabetic Renal Damage?
Current Diabetes Reviews Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Defective HIF Signaling Pathway and Brain Response to Hypoxia in Neurodegenerative Diseases: Not an “Iffy” Question!
Current Pharmaceutical Design Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Appropriate Anti-Thrombotic/Anti-Thrombin Therapy for Thrombotic Lesions
Current Cardiology Reviews